abstract：:Basal-like carcinomas represent 10 to 15% of invasive breast carcinomas and have been identified from gene expression studies. Morphologically, these tumors are undifferentiated histopronostic grade 3 carcinomas, identified in clinical practice according to their immunophenotype "triple zero" (estrogen, progesterone a...

journal_title：Bulletin du cancer

authors： Vincent-Salomon A,Macgrogan G,Charaffe-Jauffret E,Jacquemier J,Arnould L

更新日期：2010-03-01 00:00:00

abstract：:Bladder tumours are frequent with around 10,000 new cases each year in France. Less than 500 of these cases are not transitional cell carcinoma, the most frequent pathological aspect. The identification of these pathological patterns requires an initial biopsy through transurethral resection. Sarcomatoid, squamous and...

journal_title：Bulletin du cancer

authors： Boyle H,Fléchon A,Droz JP

更新日期：2010-01-01 00:00:00

abstract：:The epithelial-mesenchymal transition (EMT) is a morphogenetic program that converts epithelial into mesenchymal cells during the embryonic development. This mechanism is frequently reactivated during tumor progression and provides cells with motility and invasive capabilities favoring the metastatic dissemination fro...

journal_title：Bulletin du cancer

authors： Ansieau S,Caron de Fromentel C,Bastid J,Morel AP,Puisieux A

更新日期：2010-01-01 00:00:00

abstract：:Robotic assisted surgery is a new field of developing program for many specialties. As to head and neck oncology, the new procedure potentially offers alternatives to conventional surgery with decreased morbidity. The aim of this article is a description of the state of the art via a review of the literature. We empha...

journal_title：Bulletin du cancer

authors： Mallet Y,Moriniere S,Ceruse P,El Bedoui S

更新日期：2010-01-01 00:00:00

abstract：:A better understanding of gliomas biology is now leading to a combined histo-molecular classification of these tumors. In anaplastic gliomas ongoing studies depend on 1p/19q codeletion status and in glioblastomas on MGMT methylation status. Advanced brain tumor imaging elicits a better identification of gliomas evolut...

journal_title：Bulletin du cancer

authors： Ducray F,Dutertre G,Ricard D,Gontier E,Idbaih A,Massard C

更新日期：2010-01-01 00:00:00

abstract：:The dismal outcome of ovarian, fallopian tube, and primary peritoneal carcinomas calls for an increase in surgical aggressiveness. After a long era during which incomplete cytoreduction was considered acceptable, it has been established that the outcome is directly related to the amount of diseased tissue left in plac...

journal_title：Bulletin du cancer

authors： Querleu D,Gladieff L,Ferron G,Rougé P

更新日期：2009-12-01 00:00:00

abstract：:For several years, research for treatment of advanced ovarian cancer in first line or in relapse was made on the basis of two concepts. The first one is to improve the response rate by increasing the dose of chemotherapy delivered by high dose chemotherapy consolidation. The second concept is the development of an imm...

journal_title：Bulletin du cancer

authors： Nayl B,Cabrespine-Faugeras A,Maliki Y,Bay JO

更新日期：2009-12-01 00:00:00

abstract：:Targeted therapy against the EGF receptor was shown to be effective in a subgroup of patients with KRAS wild-type colorectal cancer. Therefore, cetuximab (Erbitux) or panitumumab (Vectibix) obtained the authorization by the EMEA restricted to patients with KRAS wild-type tumours. KRAS mutational testing has become par...

journal_title：Bulletin du cancer

authors： Blons H,Laurent-Puig P

更新日期：2009-12-01 00:00:00

abstract：:The treatment of the advanced ovarian adenocarcinoma, most frequently stage at diagnostic, relies on association of surgery and chemotherapy. The current standard is the association carboplatine-paclitaxel. In spite of this treatment, relapses are frequent, and the prognosis thus remains very reserved. Presently the c...

journal_title：Bulletin du cancer

authors： Lhommé C,Even C,Morice P,Balleyguier C,Petrella M,Gouy S,Uzan C,Duvillard P,Pautier P

更新日期：2009-12-01 00:00:00

abstract：:If chemotherapy beyond the third line often gives sum clinical benefits, it is sometimes prescribed only to avoid telling bad news to patients. Palliative chemotherapy can lead to symptom reduction and greater health related quality-of-live, but longer survival is unlikely. Physician's questioning about chemotherapy c...

journal_title：Bulletin du cancer

authors： Bouleuc C,Chvetzoff G

更新日期：2009-09-01 00:00:00

abstract：:Whereas medicine is progressing in illness treatment that used to be incurable, physicians are still faced with treatment failure. Hippocrates used to say: "primum non nocere" [1]. When the patient cannot expect benefit from potentially aggressive care, current or possible treatments have to be challenged to leave jus...

journal_title：Bulletin du cancer

authors： Laude C,Deygas S

更新日期：2009-07-01 00:00:00

abstract：:As compared to conventional axillary dissection, the sentinel node technique is accompanied by reduced morbidity and shorter hospital stay. Based on available data, the use of this technique does not seem to yield higher rates of axillary recurrence. A combination of both radioisotope detection and blue dye increases ...

journal_title：Bulletin du cancer

authors： Hindié E,Groheux D,Espie M,Bourstyn E,Toubert ME,Sarandi F,de Roquancourt A,Giacchetti S,Cuvier C,Cahen-Doidy L,Teyton P,Misset JL,Maylin C,Moretti JL

更新日期：2009-06-01 00:00:00

abstract：PURPOSE:GemOx was defined as a D1-D2 schedule, based on preclinical data. In order to improve convenience for patients, we evaluated a simplified D1-D1 GemOx regimen (S-GemOx) in MPA. PATIENTS AND METHODS:Patients (pts) with MPA were 2:1 randomly assigned for first-line treatment to S-GemOx (gemcitabine 1,000 mg/m(2),...

journal_title：Bulletin du cancer

authors： Afchain P,Chibaudel B,Lledo G,Selle F,Bengrine-Lefevre L,Nguyen S,Paitel JF,Mineur L,Artru P,André T,Louvet C

更新日期：2009-05-01 00:00:00

abstract：:Hodgkin's and non-Hodgkin's lymphomas are frequent and represent a heterogenic group of haematologic diseases. Prognostic factors allow to classify patients into homogeneic risk groups, to adapt treatment proposal to disease's risk and, in some cases, to avoid over-treatment. For all lymphomas, the first step is to de...

journal_title：Bulletin du cancer

authors： Cuenca X,Xhaard A,Mounier N

更新日期：2009-04-01 00:00:00

abstract：:Neoadjuvant chemoradiotherapy is considered at the present time as the standard treatment of most T3-4 rectal cancer. In France a combination of radiotherapy (45 Gy/5 weeks) with concurrent capecitabine (1,600 mg/m2) is the most popular protocol. Randomized trials try to optimize this approach using new cytotoxic drug...

journal_title：Bulletin du cancer

authors： Gérard JP,Francois E,Deustch E,Rostom Y,Douar N,Benezery K,Milano G

更新日期：2009-03-01 00:00:00

abstract：:Aprepitant is actually recommended in the prevention of nausea and vomiting induced by high emetic risk chemotherapy using cisplatin. We performed an observational prospective study on 101 patients evaluating the efficacy of aprepitant in the clinical conditions of use of cisplatin, out of context of clinical trial. W...

journal_title：Bulletin du cancer

authors： Galy G,Labidi SI,Tissier F,Combes JD,Auger A,Favier B,Latour JF

更新日期：2009-02-01 00:00:00

abstract：:Since the 1980's, women treated for breast cancer are reporting moderate cognitive impairments during and after chemotherapy. These cognitive impairments may be related to chemotherapy but also to hormone therapy, psychological distress, fatigue... This work is a critical review of the literature, which reports types ...

journal_title：Bulletin du cancer

authors： Vandenbossche S,Fery P,Razavi D

更新日期：2009-02-01 00:00:00

abstract：:Lung and head and neck cancers result from a multistep process involving activation of oncogenes and inactivation of tumor-suppressor genes. These two processes share common features and molecular players, while their corresponding clinical entities are both triggered by the tobacco carcinogens. In many cases, the mol...

journal_title：Bulletin du cancer

authors： Loriot Y,Mordant P,Fouret P,Deutsch E,Soria JC

更新日期：2009-01-01 00:00:00

abstract：:In 2006, a total number of 149,000 cancer deaths were observed in France, 88,500 in the male population and 60,500 in the female population. In 2005, the number of new diagnoses of cancer is estimated to be 319,000, 183,000 among men and 136,000 among women. Age-standardised mortality rates are decreasing for most fre...

journal_title：Bulletin du cancer

authors： Guérin S,Doyon F,Hill C

更新日期：2009-01-01 00:00:00

abstract：:Margin status in cervical pathology is one of most important predictive factor of recurrent disease. Even if management of surgical biopsy is standardized, quality of surgical procedure is fundamental. Frozen section can be realise in order to complete surgical procedure if margins are involved. Extemporaneous exam of...

journal_title：Bulletin du cancer

authors： Michy T,Leveque J,Loussouarn D,Dravet F,Dejode M,Sagan C,Descamps P,Classe JM

更新日期：2008-12-01 00:00:00

abstract：:Over the last decade, the development of new therapeutic options has made more patients benefit from antitumoral strategies including several lines of chemotherapy, the aim of which is a long-term control of the disease progression. In such a context of "chronic" management, the choice of tumor response as a single pa...

journal_title：Bulletin du cancer

authors： Marty M,Blay JY,Trédaniel J,Koscielny S,Hagège C,Asselain B,Goldwasser F,Misset JL

更新日期：2008-11-01 00:00:00

abstract：:Sequencing the human genome brings new tools for the individualisation of cancer chemotherapy, especially thanks to the identification of polymorphisms of genes involved in anticancer drug metabolism or activity (pharmacogenetics). A few functional polymorphisms have been known for a long time (thiopurine methyltransf...

journal_title：Bulletin du cancer

authors： Robert J,Le Morvan V

更新日期：2008-10-01 00:00:00

abstract：:In this review, we will summarize the guidelines on the evaluation of anticancer medicinal products in man and definitions for genomic biomarkers (FDA validated), pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. ...

journal_title：Bulletin du cancer

authors： Bedairia N,Marty M

更新日期：2008-10-01 00:00:00

abstract：:Based on the observation of a high incidence of breast cancer in the upper outer quadrant adjacent to the usual area of application of deodorants and/or antiperspirants, several scientific teams have advanced the hypothesis of a possible link between antiperspirants and breast cancer. The possibility of the involvemen...

journal_title：Bulletin du cancer

authors： Namer M,Luporsi E,Gligorov J,Lokiec F,Spielmann M

更新日期：2008-09-01 00:00:00

abstract：:At the time of diagnosis, central nervous system (CNS) involvement is identified in less than 10% of adult acute lymphoblastic leukemia (ALL). Long-term disease-free survival can be achieved in these patients. CNS disease at presentation does not appear to be an independent poor prognostic factor. In CNS leukemia, inn...

journal_title：Bulletin du cancer

authors： Thomas X,Pavan L,Le QH

更新日期：2008-07-01 00:00:00

abstract：:The dependency between the risk of death and age is analysed, and the contribution of cancer to the overall risk of death is evaluated as a function of age. The frequency of the different cancer sites is described in different age groups. Lastly cancer mortality trends are presented by age. The risk of death from canc...

journal_title：Bulletin du cancer

authors： Hill C,Doyon F

更新日期：2008-05-28 00:00:00

abstract：:Colorectal cancer occurs after the age of 75 in 50% of the case, but elderly patients are under-treated and far from an optimal management of their disease. Principles of colorectal cancer management after the age of 75 are theoretically the same than for younger patients, but physiological age, comorbidities and pati...

journal_title：Bulletin du cancer

authors： Mitry E

更新日期：2008-05-28 00:00:00

abstract：:Cancer patients are often moved inside the hospital to different examination clinics, such as radiology, CT scan, MRI... and to treatment clinics, such as radiotherapy. These transports induce important pain phenomena, not really recognized by professional teams. As these kinds of pains are expected and can be prevent...

journal_title：Bulletin du cancer

authors： Nebbak JM,Mathivon D,Di Palma M

更新日期：2008-05-01 00:00:00

abstract：:Bisphosphonates are potent osteoclastic inhibitors that are indicated in the prevention of bone complications. They could also be of interest in the prevention of bone metastases. Several recent international publications have highlighted the onset of osteonecrosis of the jaw (ONJ) in patients treated with bisphosphon...

journal_title：Bulletin du cancer

authors： Facon T,Bensadoun RJ,Blanc JL,Confavreux C,Gourmet R,Maes JM,Penel G,Vieillard MH,Woeller A

更新日期：2008-04-01 00:00:00

abstract：:Cancerogenesis is believed to be a multistep process composed of different alterations that drive the transformation of normal human cells into highly malignant derivatives. These changes include self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, the evasion of programmed cell death, a lim...

journal_title：Bulletin du cancer

authors： Caers J,Van Valckenborgh E,Menu E,Van Camp B,Vanderkerken K

更新日期：2008-03-01 00:00:00

abstract：:The purpose of external beam radiotherapy is to sterilize malignant tumours and at the same time to avoid complications by radiation injury to the surrounding healthy tissues. Modern radiation techniques in recent years have allowed to safely escalate the dose by approximately 10% for the treatment of prostate cancer,...

journal_title：Bulletin du cancer

authors： Soete G,Verellen D,Storme G

更新日期：2008-03-01 00:00:00

abstract：:CYP2D6 enzyme is implicated in the metabolism of drugs and nicotine. Genetic variability within CYP2D6, results in different CYP2D6 phenotypes. Inheritance of polymorphic CYP2D6 metabolizing enzyme is likely to be an important determinant of inter-individual variations in susceptibility to cancer. In this work, we hav...

journal_title：Bulletin du cancer

authors： Ouerhani S,Marrakchi R,Bouhaha R,Ben Slama MR,Sfaxi M,Ayed M,Chebil M,El Gaaied AB

更新日期：2008-02-01 00:00:00

abstract：:It is widely accepted that the development of carcinoma is not only due to somatic mutations in epithelial cells but also is influenced by the tumor microenvironment ie the stroma. The different stroma components produced growth factors, cytokines, the extra cellular matrix and also participated to the recruitment of ...

journal_title：Bulletin du cancer

authors： Billottet C,Jouanneau J

更新日期：2008-01-01 00:00:00

abstract：:Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is now an entire part of treatment of peritoneal dissemination of colorectal malignancy, and it's possible to hope prolonged survival. This treatment is more and more codified. Four indications are recognized by some tree national evaluation committees: ...

journal_title：Bulletin du cancer

authors： Eveno C,Dagois S,Guillot E,Gornet JM,Pocard M

更新日期：2008-01-01 00:00:00

abstract：:The first endoscopic gall-bladder ablation was performed in France, twenty years ago. NOTES (natural orifices transluminal endoscopic surgery) is a new step towards surgery leaving no scar. Is surgery's paradigm changing now ? This short study will focus on the epistemologic and ethical changes which have been generat...

journal_title：Bulletin du cancer

authors： Hubinois P

更新日期：2007-12-01 00:00:00

abstract：:The aims of this study was to estimate and describe the reasons of use of complementary medicine in patients with a cancer treated in a French oncology department. An anonymous questionnaire was proposed to patients during treatment or follow-up in an oncology department. It was a descriptive study over 207 questionna...

journal_title：Bulletin du cancer

authors： Träger-Maury S,Tournigand C,Maindrault-Goebel F,Afchain P,de Gramont A,Garcia-Larnicol ML,Gervais H,Louvet C

更新日期：2007-11-01 00:00:00

abstract：:The treatment of chronic myeloid leukemia (CML) has considerably evolved since imatinib mesylate has been introduced as a new therapeutic weapon for this disease. The 5-year updated results of the IRIS study confirmed that imatinib mesylate is the best first line therapy for chronic phase CML with an overall survival ...

journal_title：Bulletin du cancer

authors： Labussière H,Hayette S,Tigaud I,Michallet M,Nicolini FE

更新日期：2007-10-01 00:00:00

abstract：:Advanced stage follicular lymphoma is incurable by conventional treatment. Important progress has been observed with the development of new therapies based on monoclonal antibodies and on the use of radioimmunotherapy (RIT) in the treatment of non-Hodgkin lymphomas (NHL). Rituximab in combination with chemotherapy in ...

journal_title：Bulletin du cancer

authors： Ketterer N,Bischof Delaloye A,Helg C,Luthi F,Buchegger F

更新日期：2007-09-01 00:00:00

abstract：:Propensity score, an indicator of the propensity to get one treatment among two (or more), is encountered in non randomized studies (prospective or retrospective). It is calculated after the research of predictive factors for treatment attribution, and corresponds to the probability to receive one of the treatments co...

journal_title：Bulletin du cancer

authors： Kwiatkowski F,Slim K,Verrelle P,Chamorey E,Kramar A

更新日期：2007-07-01 00:00:00

abstract：:Androgen deprivation in patients with metastatic prostate cancer produces palliation of symptoms, PSA decrease and tumoral regression in most patients. After a brief period of disease regression lasting 18 to 24 months nearly all pts will progress to androgen independence disease (HRPC) with progressive clinical deter...

journal_title：Bulletin du cancer

authors： Gravis G,Salem N,Bladou F,Viens P

更新日期：2007-07-01 00:00:00